EA8231- A Phase III Randomized Trial of Pembrolizumab in Combination with Sacituzumab Govitecan vs Standard of Care in Anti-PD(L)1-Resistant Advanced Urothelial Cancer
Objective
To compare overall survival (OS) between the Therapy of Physician Choice (TPC) arm and the sacituzumab govitecan + pembrolizumab arm.
